EirGenix Bundle
Who Owns EirGenix?
Understanding a company's ownership is key to grasping its strategy and accountability. A significant investment by Foxconn affiliates in 2021 notably altered EirGenix Inc.'s shareholder structure.
EirGenix Inc., established in 2012, is a prominent Contract Development and Manufacturing Organization (CDMO) based in Taiwan. The company specializes in biologics manufacturing, operating PIC/S GMP-certified facilities.
Foxconn affiliates are significant stakeholders in EirGenix Inc.
Who Founded EirGenix?
EirGenix Inc. was formally established on December 21, 2012, marking the beginning of its journey in the biopharmaceutical sector. While the initial distribution of equity among its founders remains undisclosed, the company's early development was significantly influenced by a pivotal joint venture agreement. This agreement, signed in mid-March 2013, involved key partners that would shape its operational and technical foundation.
The founder, Chairman, and President of EirGenix is Dr. Liu Lee-cheng, who brings extensive experience from the biotech, pharmaceutical, and specialty chemical industries. His prior role as President and COO of AnGes Inc., a late-stage biotech enterprise, provided a strong foundation for establishing EirGenix. The company's early operational framework and technical capabilities were significantly bolstered by the transfer of assets and expertise from the Development Center for Biotechnology (DCB)-cGMP Biopharmaceutical Pilot Plant Facility. This government-commissioned facility, established in 2001, was designed to foster domestic biopharmaceutical R&D and reduce development hurdles. This foundational collaboration provided EirGenix with a robust technical base, enabling it to achieve remarkable sales growth and break even by 2016, demonstrating its early success in the competitive market. Understanding the Target Market of EirGenix is crucial to appreciating its strategic positioning from inception.
Founder and Leadership
Dr. Liu Lee-cheng is the founder, Chairman, and President of EirGenix. He possesses over 30 years of industry experience.
- Founder: Dr. Liu Lee-cheng
- Chairman: Dr. Liu Lee-cheng
- President: Dr. Liu Lee-cheng
- Previous Role: President and COO of AnGes Inc.
- Industry Experience: Over 30 years in biotech, pharmaceutical, and specialty chemical sectors.
EirGenix SWOT Analysis
- Complete SWOT Breakdown
- Fully Customizable
- Editable in Excel & Word
- Professional Formatting
- Investor-Ready Format
How Has EirGenix’s Ownership Changed Over Time?
EirGenix's ownership trajectory has been significantly shaped by strategic investments, most notably a substantial private placement in October 2021. This event marked a pivotal moment, altering the company's shareholder landscape and enabling ambitious expansion plans within the global CDMO sector.
| Investor Group | Investment Amount (NT$) | Approximate Stake |
|---|---|---|
| Foxconn Technology Co. | 2,510,000,000 | 9.1% |
| Yonglin Capital Holding Co. Ltd. | 2,420,000,000 | 8.8% |
| Hong Wei Investment Co. Ltd. | 91,500,000 | 0.3% |
The ownership evolution of EirGenix saw a significant shift in October 2021 when affiliates of Hon Hai Precision Industry Co. (Foxconn), including Foxconn Technology Co., Yonglin Capital Holding Co. Ltd., and Hong Wei Investment Co. Ltd., collectively invested NT$5.03 billion (approximately US$179.47 million at the time) through a private placement. This strategic capital infusion resulted in these Hon Hai-affiliated entities acquiring an 18.2% stake, establishing them as the largest shareholder group. Foxconn Technology Co. alone contributed NT$2.51 billion for a 9.1% stake, while Yonglin Capital Holding Co. Ltd. invested NT$2.42 billion for an 8.8% stake, and Hong Wei Investment Co. Ltd. added NT$91.5 million for a 0.3% stake. Beyond the Foxconn-linked investors, other key institutional stakeholders in EirGenix include the National Science and Technology Council and HanTech Venture. To date, EirGenix has secured a total of $480 million in funding, with its largest funding round being a Post IPO round of $90.6 million on September 22, 2021. These capital injections have been instrumental in accelerating EirGenix's global CDMO industry expansion and advancing its biosimilar pipeline, including the development of additional production lines and a focus on cell and gene therapy. The company is currently in IPO registration, with an IPO deal type announced on December 27, 2024, following a previous IPO deal type completion on June 28, 2019. EirGenix was previously listed on the Taipei Exchange (TPEX:6589) and is slated for its initial listing on the Taiwan Stock Exchange (TWSE) on July 21, 2025. Understanding EirGenix ownership is key to grasping its strategic direction and Growth Strategy of EirGenix.
Key EirGenix Stakeholders
The ownership structure of EirGenix is characterized by significant institutional backing and strategic partnerships.
- Hon Hai Precision Industry Co. (Foxconn) affiliates are the largest shareholder group.
- The National Science and Technology Council is an institutional investor.
- HanTech Venture is also among the institutional investors.
- The company has raised substantial capital through various funding rounds.
EirGenix PESTLE Analysis
- Covers All 6 PESTLE Categories
- No Research Needed – Save Hours of Work
- Built by Experts, Trusted by Consultants
- Instant Download, Ready to Use
- 100% Editable, Fully Customizable
Who Sits on EirGenix’s Board?
The Board of Directors at EirGenix Inc. is central to the company's strategic direction and governance. The leadership team is anchored by Dr. Liu Lee-cheng, who serves as Founder, Chairman, and President. This structure ensures a strong foundation of expertise and vision guiding the company's operations.
| Position | Name | Key Responsibilities |
|---|---|---|
| Founder, Chairman, and President | Dr. Liu Lee-cheng | Overall leadership and strategic direction |
| Chief Engineer | Dr. Shang-Chung Ju | Technical engineering oversight |
| CMCS and Research & Development | Dr. Irene, Ae-Ning Lin | Clinical management, safety, and R&D initiatives |
| Medical Affairs & Regulatory Affairs and Product Portfolio Management | Dr. Ywan-Feng Li | Medical strategy, regulatory compliance, and product lifecycle |
| Executive Director, Manufacturing & Technical Operation | Hark Chen | Manufacturing processes and technical operations |
In December 2022, EirGenix Inc. formalized its commitment to robust governance with the establishment of its Corporate Governance Committee. This committee includes prominent figures such as Lee-Cheng Liu (President & CEO), Ming-Thaur Chang (Independent Director, DBS Bank Ltd.), Fu-Shiow Yin (Independent Director, Foresee Pharmaceuticals Co. Ltd.), Ming-Shen Chen (Professor of Finance at National Taiwan University, serving as chairman), and Po-Chih Chen (Senior Advisors to the President). While specific voting power mechanisms like dual-class shares are not publicly detailed, the significant ownership stake held by Foxconn-affiliated entities, amounting to 18.2% as of October 2021, indicates their substantial influence through board representation and voting rights. The company's dedication to strong corporate governance is further evidenced by its recognition within the top 5% of the Corporate Governance Evaluation at TPEx following its second year post-IPO, reflecting a commitment to transparency and accountability among EirGenix stakeholders.
EirGenix Corporate Governance Highlights
EirGenix Inc. demonstrates a strong focus on corporate governance, underscored by its committee structure and market recognition.
- Establishment of a dedicated Corporate Governance Committee in December 2022.
- Inclusion of independent directors from reputable financial and pharmaceutical institutions.
- Recognition in the top 5% of TPEx Corporate Governance Evaluation.
- Significant influence from major shareholders like Foxconn-affiliated companies.
- The company's structure is designed to ensure accountability and strategic oversight, crucial for understanding Competitors Landscape of EirGenix.
EirGenix Business Model Canvas
- Complete 9-Block Business Model Canvas
- Effortlessly Communicate Your Business Strategy
- Investor-Ready BMC Format
- 100% Editable and Customizable
- Clear and Structured Layout
What Recent Changes Have Shaped EirGenix’s Ownership Landscape?
Over the past few years, EirGenix has seen significant shifts in its ownership landscape, marked by substantial investments and strategic buybacks. These changes reflect the company's evolving business priorities and its pursuit of global expansion in the biopharmaceutical sector.
| Event | Date | Details |
|---|---|---|
| Private Placement | October 2021 | Foxconn-affiliated companies became largest shareholders with 18.2% stake, investing NT$5.03 billion (approx. US$179.47 million). |
| Equity Buyback Plan | December 16, 2024 | Authorized repurchase of 4,000,000 shares (1.31% of stock) for TWD 6,357.55 million; buyback closed with 4,000,000 shares for TWD 305.47 million. |
EirGenix has made substantial strides in its product development and market penetration, notably with its breast cancer biosimilar. The European Commission granted marketing authorization for EG12014 in 2024, following a positive opinion from Sandoz AG, its commercialization partner. Further bolstering its global reach, the US FDA accepted a new drug submission for the EirGenix-Sandoz cancer drug on July 23, 2025, a development that saw EirGenix's stock increase by 6%. The company's biosimilar EIRGASUN®, marketed as Herwenda® in Europe by Sandoz, has already been launched in Taiwan and Europe. EirGenix is actively expanding its product lines, investing in cell and gene therapy, and exploring international collaborations and strategic alliances to solidify its position as a global biopharmaceutical entity. Understanding the Revenue Streams & Business Model of EirGenix provides further context to these ownership trends and strategic initiatives.
Major Shareholder Shift
In October 2021, Foxconn-affiliated entities acquired a significant 18.2% stake, becoming EirGenix's largest shareholders. This investment of approximately US$179.47 million was earmarked for R&D and operational expansion.
Share Buyback Initiative
As of December 16, 2024, EirGenix initiated an equity buyback plan, signaling a potential move to consolidate ownership or enhance shareholder value. The company repurchased 4,000,000 shares for TWD 305.47 million.
Regulatory Milestones and Market Launch
EirGenix achieved a key milestone with its breast cancer biosimilar receiving European Commission marketing authorization in 2024. The product is now available in Taiwan and Europe under different brand names.
US FDA Submission and Stock Impact
The US FDA's acceptance of a new drug submission for a cancer drug on July 23, 2025, led to a notable 6% increase in EirGenix's stock price, highlighting investor confidence in its pipeline.
EirGenix Porter's Five Forces Analysis
- Covers All 5 Competitive Forces in Detail
- Structured for Consultants, Students, and Founders
- 100% Editable in Microsoft Word & Excel
- Instant Digital Download – Use Immediately
- Compatible with Mac & PC – Fully Unlocked
- What is Brief History of EirGenix Company?
- What is Competitive Landscape of EirGenix Company?
- What is Growth Strategy and Future Prospects of EirGenix Company?
- How Does EirGenix Company Work?
- What is Sales and Marketing Strategy of EirGenix Company?
- What are Mission Vision & Core Values of EirGenix Company?
- What is Customer Demographics and Target Market of EirGenix Company?
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.